Fidelity Management & Research, an American multinational financial services corporation, lead a $97m Series C round in Antengene, an innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies. Additional investors include GL Ventures, GIC, Qiming Venture and Boyu Capital. "We appreciate the recognition and trust from these prestigious investment institutions. This round of financing has drawn support from among the world's largest asset managers, top-tier healthcare investors widely recognized in the capital markets, and strong continuous support from our existing investors. This is an important milestone to reinforce Antengene's capabilities to bring cutting-edge therapies to help patients with life-threatening diseases in the Asia Pacific regions and around the world," Jay Mei, Antengene Founder, Chairman and CEO.